Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.

Autor: Yosipovitch G; Department of Dermatology, Miami Itch Center, Miami, FL, USA., Gooderham MJ; SKiN Centre for Dermatology, Peterborough, ON, Canada., Ständer S; Department of Dermatology, Center for Chronic Pruritus, Münster University Hospital, Münster, Germany., Fonacier L; NYU Langone Hospital-Long Island Allergy and Immunology, Mineola, NY, USA., Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland., Deleuran M; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark., Girolomoni G; Department of Medicine, University of Verona, Verona, Italy., Su JC; Department of Paediatrics, Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Parkville, Australia.; Department of Dermatology, Monash University, Eastern Health, Box Hill, VIC, Australia., Bushmakin AG; Pfizer Inc., Groton, CT, USA., Cappelleri JC; Pfizer Inc., Groton, CT, USA., Feeney C; Pfizer Ltd., Surrey, UK., Chan G; Pfizer Inc., Groton, CT, USA., Thorpe AJ; Pfizer Inc., Collegeville, PA, USA., Valdez H; Pfizer Inc., New York, NY, USA., Biswas P; Pfizer Inc., New York, NY, USA., Rojo R; Pfizer Inc., Groton, CT, USA., DiBonaventura M; Pfizer Inc., New York, NY, USA., Myers DE; Pfizer Inc., Collegeville, PA, USA. Daniela.Myers@pfizer.com.

Publikováno v: American journal of clinical dermatology [Am J Clin Dermatol] 2024 Jan; Vol. 25 (1), pp. 127-138. Date of Electronic Publication: 2023 Aug 25.

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.

Autor: Simpson EL; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA., Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Nosbaum A; Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France., Winthrop KL; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA., Guttman-Yassky E; Department of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Hoffmeister KM; Versiti, Translational Glycomics Center, Blood Research Institute, Milwaukee, WI, USA.; Departments of Biochemistry and Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Egeberg A; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark., Valdez H; Pfizer Inc., New York, NY, USA., Zhang M; Pfizer Inc., La Jolla, CA, USA., Farooqui SA; Pfizer R & D UK Ltd., Kent, UK., Romero W; Pfizer Ltd., Surrey, UK., Thorpe AJ; Pfizer Inc., Collegeville, PA, USA., Rojo R; Pfizer Inc., Groton, CT, USA., Johnson S; Pfizer Inc., Collegeville, PA, USA. Susan.L.Johnson@pfizer.com.

Publikováno v: American journal of clinical dermatology [Am J Clin Dermatol] 2021 Nov; Vol. 22 (6), pp. 905.

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.

Autor: Winthrop KL; Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA., Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Baumgart DC; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada., Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria., Nduaka CI; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Lawendy N; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Chan G; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Mundayat R; Inflammation and Immunology, Pfizer Inc, New York, NY, USA., Friedman GS; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Salese L; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Thorpe AJ; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA., Su C; Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA.

Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Jun 22; Vol. 15 (6), pp. 914-929.

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.

Autor: Lichtenstein GR; Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA., Rogler G; Department of Gastroenterology and Hepatology, University of Zürich, Zürich, Switzerland., Ciorba MA; Division of Gastroenterology, Washington University in Saint Louis, Saint Louis, Missouri, USA., Su C; Pfizer Inc, Collegeville, Pennsylvania, USA., Chan G; Pfizer Inc, Collegeville, Pennsylvania, USA., Pedersen RD; Pfizer Inc, Collegeville, Pennsylvania, USA., Lawendy N; Pfizer Inc, Collegeville, Pennsylvania, USA., Quirk D; Pfizer Inc, Collegeville, Pennsylvania, USA., Nduaka CI; Pfizer Inc, Collegeville, Pennsylvania, USA., Thorpe AJ; Pfizer Inc, Collegeville, Pennsylvania, USA., Panés J; Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 May 17; Vol. 27 (6), pp. 816-825.

Multi-modal and bi-directional effects of a synthetic Δ9-Tetrahydrocannabinol (THC) analogue, Nabilone, on spatio-temporal binding windows: Evidence from the projected hand illusion.

Autor: Lim, Mark J. H.¹ (AUTHOR) mjhlpersonal@gmail.com, Iyyalol, Rajan² (AUTHOR), Lee, Joseph W. Y.² (AUTHOR), Martin-Iverson, Mathew T.¹ (AUTHOR)

Publikováno v: PLoS ONE. 9/9/2024, Vol. 19 Issue 9, p1-31. 31p.